Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Who should Pfizer buy?
Biogen Idec's sudden step onto the sale block has set off a frenzy of buyout talk. Will Pfizer buy it? According to the Wall Street Journal, Pfizer considered a Biogen deal two years ago and passed. What about Biogen's crosstown rival Genzyme, whose stock jumped on the Biogen news because it's a biotech ripe for Big Pharma plucking? It might be a better fit for Pfizer, some analysts say. Pfizer, of course, isn't talking.
- here's more about Pfizer's pass on Biogen two years ago
- check out this speculation about a Pfizer-Genzyme marriage
ALSO: Who will buy Biogen Idec? Poll
Related Articles:
Biogen Idec in play after Icahn makes his move. Report
Boston officials herald big Genzyme expansion. Report
Pfizer-Sanofi match not made in heaven? Report
Pfizer, Wyeth merger bad idea? Report
Read more on: Pfizer | Biogen Idec | Genzyme
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


